PLP2
gene geneOn this page
Also known as A4A4-LSBMGC126187
Summary
PLP2 (proteolipid protein 2, HGNC:9087) is a protein-coding gene on chromosome Xp11.23, encoding Proteolipid protein 2 (Q04941). May play a role in cell differentiation in the intestinal epithelium.
This gene encodes an integral membrane protein that localizes to the endoplasmic reticulum in colonic epithelial cells. The encoded protein can multimerize and may function as an ion channel. A polymorphism in the promoter of this gene may be linked to an increased risk of X-linked cognitive disability. A pseudogene of this gene is found on chromosome 5.
Source: NCBI Gene 5355 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 46 total
- GTEx eGene: eQTL in 45 tissues, sQTL in 9 (q < 0.05)
- MANE Select transcript:
NM_002668
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:9087 |
| Approved symbol | PLP2 |
| Name | proteolipid protein 2 |
| Location | Xp11.23 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | A4, A4-LSB, MGC126187 |
| Ensembl gene | ENSG00000102007 |
| Ensembl biotype | protein_coding |
| OMIM | 300112 |
| Entrez | 5355 |
Gene structure
Transcript identifiers
Ensembl transcripts: 7 — 5 protein_coding, 2 nonsense_mediated_decay
MANE Select: ENST00000376327
Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1, TSL 2: 1
ENST00000376327, ENST00000376322, ENST00000879549, ENST00000935268, ENST00000983336, ENST00001092619, ENST00001132492
RefSeq mRNA: 1 — MANE Select: NM_002668
NM_002668
CCDS: CCDS14319
Canonical transcript exons
ENST00000376327 — 5 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000670265 | 49174335 | 49174425 |
| ENSE00000670267 | 49173388 | 49173483 |
| ENSE00000670269 | 49173129 | 49173281 |
| ENSE00001470203 | 49174672 | 49175235 |
| ENSE00003851018 | 49171898 | 49172096 |
Expression profiles
Bgee: expression breadth ubiquitous, 267 present calls, max score 99.43.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 190.9998 / max 3605.2796, expressed in 1788 samples.
Highest expression (Bgee): gingival epithelium, gingiva, skin of abdomen, descending thoracic aorta, esophagus mucosa.
Genetic regulation across tissues (GTEx eQTL / sQTL)
PLP2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 45 tissues and its splicing (sQTL) in 9 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.
showing 20 of 54 significant tissue × QTL associations:
| Tissue | QTL | q-value | Slope | Lead variant |
|---|---|---|---|---|
| Whole Blood | eqtl | 5.0e-131 | -0.94 | X:49171812:C:A |
| Artery Tibial | eqtl | 7.4e-66 | -0.84 | X:49171812:C:A |
| Nerve Tibial | eqtl | 1.0e-60 | -0.97 | X:49171812:C:A |
| Adipose Subcutaneous | eqtl | 1.0e-50 | -0.96 | X:49171812:C:A |
| Thyroid | eqtl | 2.2e-47 | -1.06 | X:49171812:C:A |
| Artery Aorta | eqtl | 2.0e-41 | -0.97 | X:49171812:C:A |
| Lung | eqtl | 7.3e-40 | -1.09 | X:49171812:C:A |
| Adipose Visceral Omentum | eqtl | 5.0e-37 | -1.00 | X:49171812:C:A |
| Testis | eqtl | 1.8e-34 | -0.93 | X:49171812:C:A |
| Spleen | eqtl | 3.3e-34 | -1.39 | X:49171812:C:A |
| Cells Cultured fibroblasts | eqtl | 2.5e-32 | -0.52 | X:49171812:C:A |
| Heart Atrial Appendage | eqtl | 1.4e-31 | -0.98 | X:49171812:C:A |
| Muscle Skeletal | eqtl | 3.3e-31 | -0.70 | X:49171812:C:A |
| Heart Left Ventricle | eqtl | 8.5e-30 | -0.75 | X:49171812:C:A |
| Colon Sigmoid | eqtl | 5.3e-29 | -0.89 | X:49171812:C:A |
| Skin Not Sun Exposed Suprapubic | eqtl | 5.7e-28 | -0.47 | X:49171812:C:A |
| Esophagus Muscularis | eqtl | 2.7e-26 | -0.82 | X:49171812:C:A |
| Brain Putamen basal ganglia | eqtl | 4.8e-24 | -0.83 | X:49171812:C:A |
| Cells EBV-transformed lymphocytes | eqtl | 1.5e-23 | -1.30 | X:49171812:C:A |
| Pituitary | eqtl | 2.3e-23 | -0.89 | X:49171812:C:A |
FANTOM5 promoters
3 alternative TSS:
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 196320 | 114.5359 | 1777 |
| 196319 | 39.8478 | 1717 |
| 196321 | 36.6161 | 1681 |
Top tissues by expression
showing 100 of 287 tissues by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| gingival epithelium | UBERON:0001949 | 99.43 | gold quality |
| gingiva | UBERON:0001828 | 99.35 | gold quality |
| skin of abdomen | UBERON:0001416 | 99.24 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 99.20 | gold quality |
| esophagus mucosa | UBERON:0002469 | 99.17 | gold quality |
| skin of leg | UBERON:0001511 | 99.16 | gold quality |
| right coronary artery | UBERON:0001625 | 99.13 | gold quality |
| thoracic aorta | UBERON:0001515 | 99.10 | gold quality |
| ascending aorta | UBERON:0001496 | 99.09 | gold quality |
| zone of skin | UBERON:0000014 | 99.08 | gold quality |
| aorta | UBERON:0000947 | 99.05 | gold quality |
| nipple | UBERON:0002030 | 99.05 | gold quality |
| popliteal artery | UBERON:0002250 | 99.04 | gold quality |
| tibial artery | UBERON:0007610 | 99.04 | gold quality |
| upper leg skin | UBERON:0004262 | 99.03 | gold quality |
| body of pancreas | UBERON:0001150 | 99.00 | gold quality |
| tongue squamous epithelium | UBERON:0006919 | 98.98 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 98.97 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 98.96 | gold quality |
| penis | UBERON:0000989 | 98.95 | gold quality |
| vagina | UBERON:0000996 | 98.92 | gold quality |
| mammalian vulva | UBERON:0000997 | 98.92 | gold quality |
| esophagus | UBERON:0001043 | 98.91 | gold quality |
| skin of hip | UBERON:0001554 | 98.88 | gold quality |
| left coronary artery | UBERON:0001626 | 98.87 | gold quality |
| mucosa of stomach | UBERON:0001199 | 98.80 | gold quality |
| left adrenal gland cortex | UBERON:0035825 | 98.78 | gold quality |
| monocyte | CL:0000576 | 98.76 | gold quality |
| left adrenal gland | UBERON:0001234 | 98.76 | gold quality |
| right adrenal gland | UBERON:0001233 | 98.72 | gold quality |
| esophagogastric junction muscularis propria | UBERON:0035841 | 98.72 | gold quality |
| leukocyte | CL:0000738 | 98.71 | gold quality |
| coronary artery | UBERON:0001621 | 98.70 | gold quality |
| esophagus squamous epithelium | UBERON:0006920 | 98.70 | gold quality |
| mononuclear cell | CL:0000842 | 98.69 | gold quality |
| granulocyte | CL:0000094 | 98.68 | gold quality |
| mucosa of transverse colon | UBERON:0004991 | 98.64 | gold quality |
| lower esophagus | UBERON:0013473 | 98.62 | gold quality |
| lower esophagus muscularis layer | UBERON:0035833 | 98.62 | gold quality |
| epithelium of esophagus | UBERON:0001976 | 98.60 | gold quality |
| adrenal cortex | UBERON:0001235 | 98.55 | gold quality |
| oral cavity | UBERON:0000167 | 98.54 | gold quality |
| squamous epithelium | UBERON:0006914 | 98.52 | gold quality |
| right adrenal gland cortex | UBERON:0035827 | 98.51 | gold quality |
| muscle layer of sigmoid colon | UBERON:0035805 | 98.50 | gold quality |
| left uterine tube | UBERON:0001303 | 98.47 | gold quality |
| ectocervix | UBERON:0012249 | 98.40 | gold quality |
| body of uterus | UBERON:0009853 | 98.39 | gold quality |
| transverse colon | UBERON:0001157 | 98.32 | gold quality |
| upper arm skin | UBERON:0004263 | 98.30 | gold quality |
| bone marrow | UBERON:0002371 | 98.22 | gold quality |
| sigmoid colon | UBERON:0001159 | 98.19 | gold quality |
| endocervix | UBERON:0000458 | 98.17 | gold quality |
| adrenal gland | UBERON:0002369 | 98.16 | gold quality |
| bone marrow cell | CL:0002092 | 98.10 | gold quality |
| rectum | UBERON:0001052 | 98.10 | gold quality |
| hair follicle | UBERON:0002073 | 98.01 | gold quality |
| blood | UBERON:0000178 | 98.00 | gold quality |
| tendon of biceps brachii | UBERON:0008188 | 97.98 | gold quality |
| uterine cervix | UBERON:0000002 | 97.92 | gold quality |
| cervix epithelium | UBERON:0004801 | 97.84 | gold quality |
| colon | UBERON:0001155 | 97.79 | gold quality |
| large intestine | UBERON:0000059 | 97.76 | gold quality |
| right ovary | UBERON:0002118 | 97.76 | gold quality |
| mouth mucosa | UBERON:0003729 | 97.74 | gold quality |
| pancreas | UBERON:0001264 | 97.73 | gold quality |
| upper lobe of left lung | UBERON:0008952 | 97.68 | gold quality |
| endometrium epithelium | UBERON:0004811 | 97.67 | gold quality |
| upper lobe of lung | UBERON:0008948 | 97.60 | gold quality |
| right lung | UBERON:0002167 | 97.58 | gold quality |
| left ovary | UBERON:0002119 | 97.57 | gold quality |
| minor salivary gland | UBERON:0001830 | 97.54 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 97.53 | gold quality |
| islet of Langerhans | UBERON:0000006 | 97.47 | gold quality |
| adenohypophysis | UBERON:0002196 | 97.46 | gold quality |
| saphenous vein | UBERON:0007318 | 97.46 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 97.44 | gold quality |
| right atrium auricular region | UBERON:0006631 | 97.43 | gold quality |
| trabecular bone tissue | UBERON:0002483 | 97.36 | gold quality |
| body of stomach | UBERON:0001161 | 97.33 | gold quality |
| intestine | UBERON:0000160 | 97.21 | gold quality |
| pituitary gland | UBERON:0000007 | 97.18 | gold quality |
| omental fat pad | UBERON:0010414 | 97.14 | gold quality |
| adrenal tissue | UBERON:0018303 | 97.14 | gold quality |
| peritoneum | UBERON:0002358 | 97.13 | gold quality |
| body of tongue | UBERON:0011876 | 97.11 | gold quality |
| tibial nerve | UBERON:0001323 | 97.03 | gold quality |
| small intestine Peyer’s patch | UBERON:0003454 | 97.01 | gold quality |
| urinary bladder | UBERON:0001255 | 97.00 | gold quality |
| colonic mucosa | UBERON:0000317 | 96.99 | gold quality |
| mucosa of sigmoid colon | UBERON:0004993 | 96.99 | gold quality |
| fundus of stomach | UBERON:0001160 | 96.97 | gold quality |
| synovial joint | UBERON:0002217 | 96.96 | gold quality |
| myometrium | UBERON:0001296 | 96.89 | gold quality |
| cardiac atrium | UBERON:0002081 | 96.85 | gold quality |
| urethra | UBERON:0000057 | 96.81 | gold quality |
| adipose tissue of abdominal region | UBERON:0007808 | 96.79 | gold quality |
| trachea | UBERON:0003126 | 96.59 | gold quality |
| ovary | UBERON:0000992 | 96.54 | gold quality |
| subcutaneous adipose tissue | UBERON:0002190 | 96.54 | gold quality |
Single-cell (SCXA)
Detected in 23 experiment(s), a significant marker in 19.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7407 | yes | 589.97 |
| E-CURD-112 | yes | 465.65 |
| E-MTAB-6701 | yes | 89.92 |
| E-CURD-114 | yes | 72.29 |
| E-HCAD-4 | yes | 67.75 |
| E-HCAD-6 | yes | 62.05 |
| E-GEOD-125970 | yes | 24.91 |
| E-MTAB-10042 | yes | 16.56 |
| E-MTAB-9467 | yes | 16.38 |
| E-HCAD-10 | yes | 15.30 |
| E-MTAB-9067 | yes | 15.21 |
| E-MTAB-8498 | yes | 13.38 |
| E-CURD-122 | yes | 13.32 |
| E-CURD-46 | yes | 10.15 |
| E-GEOD-135922 | yes | 9.98 |
HPA expression
RNA tissue specificity: Low tissue specificity
showing 60 of 80 HPA tissues / cells by nTPM:
| Tissue / cell | Axis | nTPM | Protein (IHC) |
|---|---|---|---|
| Skin 1 | tissue | 368.8 | low |
| Bone marrow | tissue | 338.5 | medium |
| Esophagus | tissue | 257.1 | low |
| Vagina | tissue | 256.9 | low |
| Smooth muscle | tissue | 146.2 | low |
| Tonsil | tissue | 138.7 | low |
| Urinary bladder | tissue | 133.4 | low |
| Colon | tissue | 132.9 | medium |
| Rectum | tissue | 122.4 | medium |
| Adrenal gland | tissue | 112.9 | medium |
| Seminal vesicle | tissue | 98.6 | low |
| Pancreas | tissue | 97.6 | low |
| Pituitary gland | tissue | 93.3 | |
| Stomach 1 | tissue | 86.0 | medium |
| Appendix | tissue | 82.6 | medium |
| Cervix | tissue | 81.2 | medium |
| Small intestine | tissue | 80.6 | high |
| Lung | tissue | 79.3 | medium |
| Spinal cord | tissue | 79.3 | |
| Ovary | tissue | 73.5 | not detected |
| Thymus | tissue | 72.6 | |
| Endometrium 1 | tissue | 72.1 | low |
| Skeletal muscle | tissue | 67.8 | low |
| Duodenum | tissue | 66.8 | high |
| Heart muscle | tissue | 66.5 | low |
| Breast | tissue | 62.5 | medium |
| Adipose tissue | tissue | 59.4 | medium |
| Fallopian tube | tissue | 58.5 | low |
| Placenta | tissue | 57.1 | low |
| Lymph node | tissue | 56.0 | low |
| Prostate | tissue | 53.4 | low |
| Gallbladder | tissue | 49.8 | high |
| Tongue | tissue | 49.7 | |
| Salivary gland | tissue | 49.1 | low |
| Medulla oblongata | tissue | 46.7 | |
| Substantia nigra | tissue | 44.1 | |
| Epididymis | tissue | 40.3 | low |
| Hypothalamus | tissue | 39.1 | |
| Midbrain | tissue | 38.9 | |
| Pons | tissue | 36.7 | |
| Corpus callosum | tissue | 36.2 | |
| Periaqueductal gray | tissue | 35.8 | |
| Parathyroid gland | tissue | 35.2 | low |
| Spleen | tissue | 34.1 | low |
| Superior colliculi | tissue | 32.1 | |
| Thalamus | tissue | 30.6 | |
| Septum | tissue | 29.3 | |
| Choroid plexus | tissue | 28.3 | |
| Hippocampal formation | tissue | 26.3 | |
| Amygdala | tissue | 26.2 | |
| Putamen | tissue | 21.9 | |
| Ventral forebrain | tissue | 21.5 | |
| Basal ganglia | tissue | 20.1 | medium |
| Cerebral cortex | tissue | 19.2 | medium |
| Motor cortex | tissue | 19.2 | |
| Temporal cortex | tissue | 19.2 | |
| Prefrontal cortex | tissue | 19.1 | |
| Testis | tissue | 18.9 | high |
| Kidney | tissue | 18.9 | high |
| Entorhinal cortex | tissue | 18.1 |
Brain sub-regions (HPA Brain Atlas): detected in 192; highest nTPM — Blood vessel (301.1), Ventral spinal cord (79.3), Dorsal spinal cord (75.9), White matter (36.2), Subiculum (26.3).
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
Targeting PLP2 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).
showing 30 of 38 miRNAs:
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-150-5P | 99.99 | 66.69 | 1976 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-6825-5P | 99.96 | 69.81 | 3431 |
| HSA-MIR-552-5P | 99.93 | 68.56 | 1583 |
| HSA-MIR-124-3P | 99.89 | 73.74 | 3043 |
| HSA-MIR-506-3P | 99.89 | 73.55 | 3057 |
| HSA-MIR-765 | 99.84 | 68.24 | 2442 |
| HSA-MIR-6756-5P | 99.82 | 67.97 | 2466 |
| HSA-MIR-11181-3P | 99.75 | 66.38 | 2205 |
| HSA-MIR-2681-5P | 99.75 | 67.64 | 1655 |
| HSA-MIR-6892-3P | 99.68 | 66.40 | 1178 |
| HSA-MIR-6766-5P | 99.68 | 67.70 | 2325 |
| HSA-MIR-7-5P | 99.67 | 70.53 | 1809 |
| HSA-MIR-4527 | 99.66 | 67.43 | 714 |
| HSA-MIR-7150 | 99.62 | 66.80 | 1322 |
| HSA-MIR-6503-5P | 99.62 | 66.96 | 597 |
| HSA-MIR-6716-5P | 99.56 | 68.62 | 1244 |
| HSA-MIR-12123 | 99.52 | 71.79 | 2990 |
| HSA-MIR-642A-5P | 99.51 | 65.10 | 1152 |
| HSA-MIR-3678-3P | 99.31 | 67.10 | 1432 |
| HSA-MIR-1273H-3P | 99.29 | 67.55 | 980 |
| HSA-MIR-3692-5P | 99.29 | 67.04 | 1421 |
| HSA-MIR-5582-5P | 99.27 | 71.42 | 1879 |
| HSA-MIR-664A-3P | 99.22 | 71.08 | 2696 |
| HSA-MIR-4777-3P | 99.15 | 68.92 | 626 |
| HSA-MIR-6768-3P | 99.14 | 67.38 | 1319 |
| HSA-MIR-4651 | 99.06 | 67.57 | 2002 |
| HSA-MIR-3164 | 99.02 | 68.39 | 1071 |
| HSA-MIR-6820-3P | 99.02 | 68.50 | 1035 |
| HSA-MIR-1843 | 98.97 | 66.07 | 838 |
Functional genomics
Regional missense constraint (gnomAD RMC): no regional variation along ENST00000376327 — one region, missense o/e 1.03.
Literature-anchored findings (GeneRIF, showing 16)
- PLP2/A4 has a role in the chemotactic processes via CCR1 (PMID:15474493)
- PLP2 is expressed abundantly in the pyramidal cells of hippocampus and granular cells of the cerebellum in the brains of a cohort of males with probable X-linked mental retardation. (PMID:17416750)
- This work ascribes a critical function to PLP2 for viral ligase activity and underlines the power of non-lethal haploid genetic screens in human cells to identify the genes involved in pathogen manipulation of the host immune system. (PMID:24278019)
- PLP2 and RAB5C are binding partners of TPD52. (PMID:24604726)
- PLP2 specifically binds to phosphatidylinositol 3 kinase to activate the protein kinase B pathway to enhance cell proliferation, adhesion, and invasion in melanoma cells. (PMID:26287415)
- Up-regulation of miR-422a attenuated microsphere formation, proliferation and tumor formation of breast cancer stem cells via suppressing the PLP2 expression. (PMID:29509055)
- Higher PLP2 immunohistochemistry staining significantly correlated with more advanced tumor grades and poorer prognosis in human gliomas. (PMID:30373180)
- Reduced expression of proteolipid protein 2 increases ER stress-induced apoptosis and autophagy in glioblastoma. (PMID:31778016)
- MiR-765 functions as a tumour suppressor and eliminates lipids in clear cell renal cell carcinoma by downregulating PLP2. (PMID:31901870)
- PLP2 Expression as a Prognostic and Therapeutic Indicator in High-Risk Multiple Myeloma. (PMID:32596309)
- CD45RO(-)CD8(+) T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ERbeta/miR-765/PLP2/Notch axis. (PMID:33859750)
- PLP2 drives collective cell migration via ZO-1-mediated cytoskeletal remodeling at the leading edge in human colorectal cancer cells. (PMID:34409455)
- PLP2-derived peptide Rb4 triggers PARP-1-mediated necrotic death in murine melanoma cells. (PMID:35190586)
- Structural basis of plp2-mediated cytoskeletal protein folding by TRiC/CCT. (PMID:36921056)
- Low Expression of A3C and PLP2 Indicating a Favorable Prognosis in Human Gliomas. (PMID:37715423)
- Reduced Proteolipid Protein 2 promotes endoplasmic reticulum stress-related apoptosis and increases drug sensitivity in acute myeloid leukemia. (PMID:38085372)
Cross-species orthologs
8 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | plp2b | ENSDARG00000036630 |
| danio_rerio | plp2a | ENSDARG00000042972 |
| mus_musculus | Plp2 | ENSMUSG00000031146 |
| mus_musculus | Plp2rt | ENSMUSG00000057762 |
| rattus_norvegicus | Plp2 | ENSRNOG00000039496 |
| rattus_norvegicus | Plp2l1 | ENSRNOG00000055728 |
| caenorhabditis_elegans | F28H1.4 | WBGENE00017909 |
| caenorhabditis_elegans | F47B3.3 | WBGENE00018527 |
Paralogs (14): CMTM1 (ENSG00000089505), CMTM6 (ENSG00000091317), PLLP (ENSG00000102934), CMTM3 (ENSG00000140931), CMTM2 (ENSG00000140932), MALL (ENSG00000144063), MAL2 (ENSG00000147676), CMTM7 (ENSG00000153551), MARVELD1 (ENSG00000155254), CMTM5 (ENSG00000166091), CMTM8 (ENSG00000170293), MAL (ENSG00000172005), CMTM4 (ENSG00000183723), CKLF (ENSG00000217555)
Mouse-model phenotypes
Observed phenotypes of the mouse ortholog (MGI:1298382) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 6 distinct phenotype terms.
| Mouse phenotype (MP) | Records |
|---|---|
| increased susceptibility to ischemic brain injury | 1 |
| increased neuron apoptosis | 1 |
| abnormal endoplasmic reticulum morphology | 1 |
| increased fibroblast apoptosis | 1 |
| increased endoplasmic reticulum stress | 1 |
| abnormal Golgi vesicle transport | 1 |
Additional cross-species homologs
Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.
| Organism | UniProt | Identity | Method |
|---|---|---|---|
| Oryctolagus cuniculus | Q95MN6 | 88.2% | Diamond |
| Bos taurus | Q6Y1E2 | 87.5% | Diamond |
| Ovis aries | Q28597 | 82.7% | Diamond |
Genomic neighbors (locus context)
Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).
| Symbol | Type | Entrez |
|---|---|---|
| PRICKLE3 | protein-coding | 4007 |
| SYP | protein-coding | 6855 |
| CACNA1F | protein-coding | 778 |
| MAGIX | protein-coding | 79917 |
| WDR45 | protein-coding | 11152 |
| GPKOW | protein-coding | 27238 |
| SYP-AS1 | ncRNA | 100873921 |
| CCDC22 | protein-coding | 28952 |
| FOXP3 | protein-coding | 50943 |
Protein
Protein identifiers
Proteolipid protein 2 — Q04941 (reviewed: Q04941)
Alternative names: Differentiation-dependent protein A4, Intestinal membrane A4 protein
All UniProt accessions (1): Q04941
UniProt curated annotations — full annotation on UniProt →
Function. May play a role in cell differentiation in the intestinal epithelium.
Subcellular location. Membrane.
Tissue specificity. Enriched in colonic mucosa. The expression of A4 follows a gradient along the crypto-villus axis with the most abundant message occurring in the lower half of the crypt.
Isoforms (2)
| UniProt ID | Names | Canonical? |
|---|---|---|
| Q04941-1 | 1 | yes |
| Q04941-2 | 2 |
RefSeq proteins (1): NP_002659* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR008253 | Marvel | Domain |
| IPR050578 | MARVEL-like | Family |
Pfam: PF01284
UniProt features (10 total): transmembrane region 4, glycosylation site 2, chain 1, domain 1, splice variant 1, sequence variant 1
Structure
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q04941-F1 | 78.76 | 0.22 |
Human Protein Atlas
Protein class: Transporters, Transporter channels and pores, Predicted membrane proteins
Protein evidence: Evidence at protein level
Antibody reliability (HPA): IH approved
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Glycosylation sites (2)
| Type | Positions |
|---|---|
| N-linked (glcnac…) asparagine | 18, 108 |
Function
Pathways and Gene Ontology
Reactome pathways
0 curated (TAS) of 0; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).
MSigDB gene sets: 314 (showing top):
RNGTGGGC_UNKNOWN, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, HORIUCHI_WTAP_TARGETS_DN, GOBP_RESPONSE_TO_PEPTIDE, XU_GH1_AUTOCRINE_TARGETS_UP, JAEGER_METASTASIS_DN, MODULE_151, GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_UP, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, HSIAO_HOUSEKEEPING_GENES, GGGTGGRR_PAX4_03, AAAYRNCTG_UNKNOWN, TTGGGAG_MIR150
GO Biological Process (4): monoatomic ion transport (GO:0006811), chemotaxis (GO:0006935), cytokine-mediated signaling pathway (GO:0019221), monoatomic ion transmembrane transport (GO:0034220)
GO Molecular Function (3): monoatomic ion transmembrane transporter activity (GO:0015075), chemokine binding (GO:0019956), protein binding (GO:0005515)
GO Cellular Component (4): endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), plasma membrane (GO:0005886), membrane (GO:0016020)
GO top-level categories
20 GO namespaces:
| Category | Terms |
|---|---|
| transport | 1 |
| response to chemical | 1 |
| taxis | 1 |
| cell surface receptor signaling pathway | 1 |
| cellular response to cytokine stimulus | 1 |
| monoatomic ion transport | 1 |
| transmembrane transport | 1 |
| transmembrane transporter activity | 1 |
| monoatomic ion transmembrane transport | 1 |
| cytokine binding | 1 |
| binding | 1 |
| cytoplasm | 1 |
| endomembrane system | 1 |
| intracellular membrane-bounded organelle | 1 |
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| membrane | 1 |
| cell periphery | 1 |
| cellular anatomical structure | 1 |
Experimentally-supported GO annotations
GO terms backed by direct experimental evidence (ECO experimental codes) — 2 of 11 annotations. The rest are phylogenetic / computational / electronic (IEA).
2 experimentally-supported GO terms:
| GO term | NS | Evidence |
|---|---|---|
| plasma membrane | CC | direct assay |
| chemokine binding | MF | physical interaction |
Protein interactions and networks
STRING
showing 15 of 610 interactions by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| PLP2 | PLP1 | P04400 | 974 |
| PLP2 | PDCL2 | Q8N4E4 | 898 |
| PLP2 | PDC | P20941 | 888 |
| PLP2 | PDCL3 | Q9H2J4 | 865 |
| PLP2 | SUCLG2 | Q96I99 | 747 |
| PLP2 | TUBB2A | Q13885 | 639 |
| PLP2 | CGA | P01215 | 630 |
| PLP2 | TUBB | P05218 | 618 |
| PLP2 | TCP1 | P17987 | 613 |
| PLP2 | ZUP1 | Q96AP4 | 519 |
| PLP2 | SH2D3C | Q8N5H7 | 509 |
| PLP2 | PPP1CA | P08129 | 492 |
| PLP2 | ISG15 | P05161 | 477 |
| PLP2 | IRF3 | Q14653 | 457 |
| PLP2 | SH2D3A | Q9BRG2 | 453 |
IntAct
Human interaction partners of PLP2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).
showing 30 of 68 partners by confidence:
| Partner | Interaction type | MIscore | Records |
|---|---|---|---|
| TMEM79 | physical association | 0.670 | 4 |
| CCR1 | physical association | 0.660 | 3 |
| TMPRSS2 | physical association | 0.600 | 4 |
| ARFIP2 | physical association | 0.560 | 5 |
| PACC1 | physical association | 0.560 | 5 |
| AQP3 | physical association | 0.560 | 3 |
| AQP8 | physical association | 0.560 | 3 |
| ASGR2 | physical association | 0.560 | 3 |
| ATP5PF | physical association | 0.560 | 3 |
| BIK | physical association | 0.560 | 3 |
| BNIP3 | physical association | 0.560 | 3 |
| CD53 | physical association | 0.560 | 3 |
| CD79A | physical association | 0.560 | 3 |
| CERS4 | physical association | 0.560 | 3 |
| CIAO2A | physical association | 0.560 | 3 |
| CLDN5 | physical association | 0.560 | 3 |
| CPLX4 | physical association | 0.560 | 3 |
| CRB3 | physical association | 0.560 | 3 |
| CREB3L1 | physical association | 0.560 | 3 |
| CYB561 | physical association | 0.560 | 3 |
| CYBC1 | physical association | 0.560 | 3 |
| CYBRD1 | physical association | 0.560 | 3 |
| DARS2 | physical association | 0.560 | 3 |
| DNAJC1 | physical association | 0.560 | 3 |
| EBP | physical association | 0.560 | 3 |
| ELOVL5 | physical association | 0.560 | 3 |
| EVI2A | physical association | 0.560 | 3 |
| FAM209A | physical association | 0.560 | 3 |
| FAM210B | physical association | 0.560 | 3 |
| FATE1 | physical association | 0.560 | 3 |
BioGRID (123 interactions; top human partners by supporting records): LACC1 (Affinity Capture-MS; 2 records), AQP2 (Two-hybrid), AQP3 (Two-hybrid), AQP6 (Two-hybrid), AQP8 (Two-hybrid), ARFIP2 (Two-hybrid), ARL13B (Two-hybrid), ASGR2 (Two-hybrid), ATP5J (Two-hybrid), BIK (Two-hybrid), BNIP3 (Two-hybrid), C17orf62 (Two-hybrid), C9orf72 (Affinity Capture-MS), CCDC155 (Two-hybrid), CCR1 (Affinity Capture-MS)
Disease & clinical
Genetic variants
Variant evidence for PLP2: 46 ClinVar records (0 pathogenic / likely pathogenic); 1 GWAS association.
ClinVar
46 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 17 |
| Likely benign | 2 |
| Benign | 1 |
SpliceAI
Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 26 predictions of 413):
| Position(s) | Effect | Δscore | Sites |
|---|---|---|---|
| X:49172074 | donor_gain | 1.0000 | |
| X:49173380 | acceptor_gain | 1.0000 | |
| X:49173386–49173387 | acceptor_loss | 1.0000 | 4 |
| X:49173613 | donor_gain | 1.0000 | |
| X:49173668 | donor_gain | 1.0000 | |
| X:49174325 | acceptor_gain | 1.0000 | |
| X:49174333–49174334 | acceptor_loss | 1.0000 | 6 |
| X:49174426–49174427 | donor_loss | 1.0000 | 5 |
| X:49173127–49173128 | acceptor_loss | 0.9900 | 5 |
| X:49173255 | donor_gain | 0.9900 |
AlphaMissense
256 missense substitutions predicted likely pathogenic (of 974 scored), across 87 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:
| Residue | Likely-pathogenic substitutions | Mean am_pathogenicity | Max am_pathogenicity |
|---|---|---|---|
| D84 | 8 | 0.912 | 0.955 |
| D128 | 8 | 0.888 | 0.923 |
| F125 | 7 | 0.910 | 0.952 |
| W80 | 7 | 0.884 | 0.983 |
| F19 | 7 | 0.868 | 0.948 |
| F42 | 7 | 0.854 | 0.962 |
| E31 | 6 | 0.873 | 0.956 |
| M57 | 6 | 0.867 | 0.956 |
| K24 | 6 | 0.856 | 0.950 |
| E56 | 6 | 0.822 | 0.921 |
| G115 | 5 | 0.932 | 0.968 |
| G25 | 5 | 0.886 | 0.983 |
| Y95 | 5 | 0.851 | 0.954 |
| G118 | 5 | 0.833 | 0.984 |
| C16 | 5 | 0.764 | 0.938 |
| C12 | 5 | 0.699 | 0.832 |
| F64 | 5 | 0.693 | 0.716 |
| C35 | 4 | 0.942 | 0.981 |
| S83 | 4 | 0.880 | 0.974 |
| F85 | 4 | 0.858 | 0.870 |
HPA cancer prognostics
RNA cancer specificity: Low cancer specificity
Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.
4 prognostic cancer types:
| Cancer | Prognostic | p-value |
|---|---|---|
| Kidney Renal Clear Cell Carcinoma (TCGA) | unfavorable | 1.7e-05 |
| Lung Adenocarcinoma (validation) | unfavorable | 2.07e-05 |
| Glioblastoma Multiforme (validation) | unfavorable | 0.000335 |
| Liver Hepatocellular Carcinoma (TCGA) | unfavorable | 0.000369 |
Disease associations
OMIM: gene MIM:300112 | disease phenotypes:
GWAS associations
1 associations:
| Study | Trait | p-value |
|---|---|---|
| GCST90002401_293 | Platelet distribution width | 9e-10 |
EFO canonical traits (from GWAS)
1 canonical traits:
| EFO ID | Trait name |
|---|---|
| EFO:0007984 | platelet component distribution width |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: yes
ChEMBL targets (1): CHEMBL6067398 (SINGLE PROTEIN)
PharmGKB: 1 entry (CPIC guideline: no)
Binding affinities (BindingDB)
1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.
| Ligand | Measure | Value |
|---|---|---|
| CHEMBL5653589 | KD | 1440 nM |
CTD chemical–gene interactions
45 total (human), top 30 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| Valproic Acid | affects cotreatment, increases expression, affects expression, decreases expression | 9 |
| Cadmium Chloride | decreases reaction, increases abundance, increases palmitoylation, decreases expression, increases expression | 3 |
| bisphenol A | affects cotreatment, decreases methylation, decreases expression | 2 |
| entinostat | increases expression, affects cotreatment | 2 |
| Benzo(a)pyrene | increases methylation, affects methylation, increases expression | 2 |
| Cadmium | decreases reaction, increases abundance, increases palmitoylation, decreases expression | 2 |
| Doxorubicin | decreases expression, affects expression | 2 |
| Tretinoin | decreases expression | 2 |
| aristolochic acid I | decreases expression | 1 |
| dicrotophos | increases expression | 1 |
| triphenyl phosphate | affects expression | 1 |
| salinomycin | decreases expression | 1 |
| beta-lapachone | increases expression | 1 |
| methylparaben | increases expression | 1 |
| sodium arsenite | increases expression | 1 |
| 2-bromopalmitate | decreases reaction, increases abundance, increases palmitoylation | 1 |
| cadmium acetate | decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| CD 437 | decreases expression | 1 |
| deguelin | increases expression | 1 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide | affects cotreatment, increases expression | 1 |
| dorsomorphin | increases expression, affects cotreatment | 1 |
| jinfukang | increases expression | 1 |
| (+)-JQ1 compound | decreases expression | 1 |
| Resveratrol | increases expression | 1 |
| Temozolomide | decreases expression | 1 |
| Decitabine | increases expression | 1 |
| Fulvestrant | affects cotreatment, decreases methylation | 1 |
| Acetaminophen | decreases expression | 1 |
| Atrazine | decreases expression | 1 |
ChEMBL screening assays
1 unique, capped per target: 1 binding
Representative assays (with source publication via chembl_document):
| Assay ID | Type | Description | Source paper |
|---|---|---|---|
| CHEMBL5652069 | Binding | Binding affinity to human PLP2 incubated for 45 mins by Kinobead based pull down assay | NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — *ChemMedChem* |
Cellosaurus cell lines
2 cell lines: 2 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_TE70 | HAP1 PLP2 (-) 1 | Cancer cell line | Male |
| CVCL_TE71 | HAP1 PLP2 (-) 2 | Cancer cell line | Male |
Clinical trials (associated diseases)
Via MONDO — disease-level, not drug-specific.
Predicted chemistry — Sugi Predict
The predicted patent-compound landscape for PLP2 across ~30M SureChEMBL compounds — explore on Sugi Predict.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.